Almac Group’s Dundalk Site Achieves Globally Recognised Health & Safety and Environmental Management System Certifications
August 18, 2022
A key advancement in Almac’s global Corporate Social Responsibility strategy
Almac’s European Campus in Dundalk has today been recommended for full certification to the International Organisation for Standardisation (ISO) standards 45001 and 14001 after a full UKAS Accredited audit of the Integrated Management System (IMS).
ISO is an independent, non-governmental, international organisation that produces standards to support innovation and provide solutions to global challenges. The standards achieved are globally recognised for Operational Health & Safety and Environmental Management.
The integrated framework provides all managers and employees with guidance and support regarding the management of HSE, from identifying and handling risks to evaluating and continuously improving processes and is continually updated and improved through regular assessments, reviews and internal audits. The certification of our European Campus is part of Almac’s ongoing strategy to roll out ISO 45001 and ISO 14001 certification across the group’s global sites with an ambition to certify Singapore in 2023 and begin the process for our US sites in 2024.
Almac Group opened the Dundalk facility in 2017, as part of its ongoing global expansion strategy to meet client demand. The site is complementary to the group’s existing clinical supply and drug product development operations offered from its global headquarters in Craigavon, Northern Ireland.
Niall Harkin, Executive Director, Almac Group says: “Almac Group is committed to operating as a responsible business and being a good corporate neighbour across all our sites globally. We are therefore dedicated to implementing the highest standards in sustainability, health and safety into our business. Thank you to everyone involved in our success, including all my colleagues at the Dundalk site, and the Global HSE team who supported the preparations and execution.”
About Almac Group
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally.
Our innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation that has grown organically over the past five decades now employing over 6,500 highly skilled personnel across 18 facilities including Europe, the US and Asia.
We have a global reputation for excellence built over 50 years of client service, delivering expertise right across the drug development lifecycle and offering a tailored solution to each of our clients.
To keep up to date with our latest news, follow us on Twitter and LinkedIn or visit almacgroup.com.